{"entity":{"id":"alisertib","kind":"drug","name":"Alisertib","aka":["PB-8237","MLN8237"],"tldr":"Alisertib is an oral serine/threonine kinase inhibitor from Puma Biotechnology, Inc., in registered phase 2 trials for small-cell lung cancer.","summary":"Alisertib is listed on ClinicalTrials.gov as an intervention in 5 registered phase 2 trials sponsored by Puma Biotechnology, Inc., in small-cell lung cancer. A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Alisertib","url":"https://clinicaltrials.gov/search?intr=Alisertib"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["puma-biotechnology"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07465757","nct07465757","nct07465757","nct07465757","nct07465757"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"modality":"Oral serine/threonine kinase inhibitor","mechanism":"A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/alisertib/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"company":[{"id":"puma-biotechnology","kind":"company","name":"Puma Biotechnology","route":"/companies/puma-biotechnology/"}],"trial":[{"id":"nct07465757","kind":"trial","name":"A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)","route":"/trials/nct07465757/"},{"id":"nct06369285","kind":"trial","name":"A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer","route":"/trials/nct06369285/"},{"id":"nct06095505","kind":"trial","name":"A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer","route":"/trials/nct06095505/"}]}}